MetroHealth — Cleveland, Ohio

Public research footprint of MetroHealth, compiled from the ClinicalTrials.gov public registry.

798

Registered studies

193

Active

Recruiting now

482

Completed

Stopped or withdrawn

Most-studied conditions

Lung Non-Squamous Non-Small Cell Carcinoma · EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified · Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma · Metastatic Non-Cutaneous Melanoma

Recently updated registry entries

NCT03258554 — Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally… (Completed)
NCT04267848 — Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy… (Recruiting)
NCT03907488 — Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in… (Active Not Recruiting)

7 more recent registry entries at this facility

Enter your work email to view the full list.

I’d also like to receive occasional marketing emails from Eichor for research sites (optional — unsubscribe anytime).

Work at MetroHealth?

Verify and correct how your facility appears in public registry records — free.

Verify this profile →

Compiled from public registry records (ClinicalTrials.gov) as of August 04, 2026. Counts reflect how this facility appears in registry listings; name variants may exist and are not combined. This page describes public records only and makes no assessment of any facility.